NASDAQ
Journey Medical Corporation (DERM)
♥ 688 Thanks from members
Journey Medical Corporation (DERM) demonstrates strong commercial momentum driven by its flagship rosacea treatment Emrosi, achieving 23% Q2 revenue growth and narrowing net losses, though lingering going concern flags and legacy product declines temper the overall outlook.